Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

V de Haas,Ojhm Verhagen,AEGKr von dem Borne,W. Kroes,H. van den Berg,C. E. Van Der Schoot

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

2001

V de Haas
Ojhm Verhagen
AEGKr von dem Borne
W. Kroes
H. van den Berg
C. E. Van Der Schoot

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy

Keywords:

Minimal residual disease
INDUCTION TREATMENT
Acute lymphocytic leukemia
Cancer research
Antigen
Lymphoblastic Leukemia
Medicine
Chemotherapy
Immunoglobulin heavy chain
T-cell receptor
gene rearrangement
Biology
Real-time polymerase chain reaction
Immunology
Somatic evolution in cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations